Accueil   Diary - News   All news IXALTIS starts first clinical trial of Litoxetine in USA

IXALTIS starts first clinical trial of Litoxetine in USA

 

 

Toulouse (31) / Archamps (74), April 9th, 2018 -  Following the acceptance by the Food and Drug Administration of its Investigational New Drug (IND) application for Litoxetine in September 2017, Ixaltis is now launching its first clinical trial in the US.
 


This double blind randomized placebo-controlled study will explore the safety, tolerability and efficacy of oral litoxetine, a highly Selective Serotonin Reuptake Inhibitor (SSRI) and Multiple Serotonin Agonist-Antagonist, provided by dose titration to subjects suffering from urinary incontinence.

 


Over eight weeks, the safety profile of Litoxetine will be explored together with effect measures such as frequency of incontinence episodes, change in rate of nocturia, and change in usage of incontinence pads.

 

 

Read the press release